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The earlier an activation of a G protein-dependent signalling cascade at a G protein-coupled receptor 
(GPCR) is probed, the less amplificatory effects contribute to the measured signal. This is especially 
useful in case of a precise quantification of agonist efficacies, and is of paramount importance, when 
determining agonist bias in relation to the β-arrestin pathway. As most canonical assays with medium 
to high throughput rely on the quantification of second messengers, and assays affording more 
proximal readouts are often limited in throughput, we developed a technique with a proximal readout 
and sufficiently high throughput that can be used in live cells. Split luciferase complementation (SLC) 
was applied to assess the interaction of Gαq with its effector phospholipase C-β3. The resulting probe 
yielded an excellent Z’ value of 0.7 and offers a broad and easy applicability to various Gαq-coupling 
GPCRs (hH1R, hM1,3,5R, hNTS1R), expressed in HEK293T cells, allowing the functional characterisation 
of agonists and antagonists. Furthermore, the developed sensor enabled imaging of live cells by 
luminescence microscopy, as demonstrated for the hM3R. The versatile SLC-based probe is broadly 
applicable e.g. to the screening and the pharmacological characterisation of GPCR ligands as well as to 
molecular imaging.
G protein-coupled receptors (GPCR) consist of seven transmembrane helices and are responsible for transducing 
stimuli, e.g. by hormones or neurotransmitters, across the cellular membrane. They represent the largest of all 
protein superfamilies in the human genome comprising more than 1000 different receptors1, and are the most 
important drug targets with approximately 34% of all drugs addressing GPCRs2. Agonist binding to a GPCR leads 
to the activation of heterotrimeric G proteins comprising an α, β and γ subunit. Binding of an agonist to a GPCR 
leads to a structural rearrangement resulting in an exchange of GDP for GTP within the α subunit.
There are four major subfamilies of Gα proteins of which we focussed on the αq type that upon activation 
of the receptor, interacts with effector proteins of the phospholipase C (PLC) class and triggers their enzymatic 
activity. PLCs catalyse the formation of inositol trisphosphate (IP3) and diacylglycerol (DAG) from phosphati-
dylinositol 4,5-bisphosphate. DAG diffuses in the cell membrane, whereas IP3 activates Ca2+ channels within the 
membrane of the endoplasmic reticulum and/or the cellular membrane, both leading to a transient increase in 
the concentration of Ca2+ in the cytosol. The latter is involved in a plethora of physiological processes such as 
rearrangements of the cytoskeleton and regulation of gene transcription3.
In case of the second messengers IP3 and Ca2+, changes in intracellular levels are usually measured by 
liquid-scintillation counting or luminometry. When cells are incubated with tritiated myo-inositol, radioactive 
IP3 (IP1, IP2) levels can be determined4, whereas Förster resonance energy transfer (FRET)5- and split-luciferase 
complementation (SLC)-based6 assays make use of specific interactions of IP1 or IP3 with various optical probes. 
Most often intracellular Ca2+ levels are measured either with fluorescent chelators, changing their optical proper-
ties upon complexation of Ca2+ ions7–9 or a calcium-dependent luciferase (aequorin)7,10.
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However, substantial amplification, taking place with every step in the signalling cascade, potentially masking 
effects at earlier stages11 can lead to misinterpretation, e.g. partial agonists appear as a full agonists in assays with a 
distal readout3,12. Furthermore, since there is an increasing interest in the discrimination of biased agonism with 
respect to G protein-dependent and β-arrestin-dependent pathways13, techniques are needed, allowing a proxi-
mal quantification of signalling events14. Such methods comprise [35S]GTPγS-incorporation15 and steady-state 
[32,33P]-based GTPase assays16 or FRET17- and bioluminescence resonance energy transfer (BRET)-based 
techniques18.
Most of the aforementioned approaches are compromised e.g. by requiring cell lysis, the preparation of 
membranes, the availability of radiolabelled chemicals or by low throughput. To overcome these limitations, we 
decided to use SLC to quantify the interaction of Gαq with PLC-β3. This technology is based on two catalytically 
inactive complementary fragments of a luciferase, reconstituting a functional enzyme, catalysing the oxidation of 
a substrate with concomitant emission of light, when brought in close proximity19. The two fragments are fused 
to two proteins of which a specific interaction is expected, in this case Gαq and PLC-β3. Probes, based on SLC, 
have become valuable tools for the quantification of protein-protein interactions (PPI) in general20–22, but also in 
the field of GPCR research. In this context, SLC was successfully applied to probe the interaction of β-arrestins 
with GPCRs23–25 and to the quantification of second messengers such as cAMP26 and IP36,26. Advantages of SLC 
involve a high signal-to-background (S/B) ratio, enabling live cell and in vivo imaging27 and the availability of 
luciferases catalysing chemical reactions, accompanied by the emission of bright light of different wavelengths 
(broad spectral diversity)28–30.
We applied SLC to probe the Gαq/PLC-β3 interaction (Fig. 1A) by means of a modified luciferase from the 
click-beetle Pyrophorus plagiophthalamus (λmax = 613 nm). The enzyme was split into two fragments, a larger 
N-terminal fragment (CBRN) consisting of the amino acids 1–416 and a smaller C-terminal fragment (CBRC) 
composed of amino acids 395–542. We generated two sets of fusion proteins of which the first one represents 
CBRN fused either N-, or C-terminally to PLC-β3 and in the second one CBRC was fused terminally to Gαq. 
As both termini of Gα subunits are known to be crucial not only for interactions with a respective GPCR the 
βγ-complex but also for the association with the cellular membrane31–34, CBRC was also integrated in three dif-
ferent flexible loop regions of Gαq. The combination of those fusion proteins, giving the highest S/B ratio upon 
complementation was used as a sensor to probe the activation of different Gαq-coupled receptors. We demon-
strate that the new probe is of value for the functional characterisation of GPCR ligands and for imaging receptor 
activation in live cells.
Material and Methods
Materials. Dulbecco’s modified Eagle’s medium (DMEM) with and without phenol red and phosphate-buff-
ered saline (PBS) were from Sigma (Germany). Leibovitz’ L-15 medium (L-15) and Hank’s balanced salt solution 
(HBSS) were from Gibco (Germany). Fura-2 AM, fetal calf serum (FCS), trypsin and geneticin (G418) were 
from Merck Biochrom (Germany). D-Luciferin was purchased as potassium salt either from Wako (Japan) or 
from Pierce (Germany) and was dissolved in HBSS at a concentration of 400 mM. Puromycin was obtained from 
Invivogen (France). The pCBR-control vector and the Bright-Glo luciferase assay reagent were from Promega 
(Japan and Germany). The pcDNA4 vector was from Thermo Scientific (Germany), whereas the pIRESpuro3 
vector was from Clontech (France). Depending on their physicochemical properties, when possible, ligands were 
dissolved in H2O; otherwise DMSO (Merck) was used as solvent. Histamine dihydrochloride (his), was from 
Acros Organics (Belgium), betahistine dihydrochloride (betahis), diphenhydramine hydrochloride (diph), cypro-
heptadine hydrochloride (cyp), maprotiline hydrochloride (map), carbachol chloride (car), iperoxo iodide (iper), 
N-methyl scopolamine bromide (NMS), atropine (atr), propantheline bromide (prop) and pirenzepine dihydro-
chloride (pir) were from Sigma (Germany), whereas mepyramine maleate (mep) was from Tocris Bioscience 
(MO, USA). UR-KUM530 (KUM530)35 and histaprodifen (histapro) were kindly provided by Prof. Dr. Sigurd 
Elz (University of Regensburg, Germany). Oxotremorine sesquifumarate (oxo) was from MP Biomedicals 
(CA, USA), xanomeline (xan) was synthesized in-house according to a standard procedure36. Neurotensin 
(8–13) (NT(8-13)) was from Synpeptide (China). SR142948A was gift from Dr. Harald Hübner (University of 
Erlangen, Germany). FR900359 was purchased from the Institute of Pharmaceutical Biology, University of Bonn 
(Germany).
Cell cultivation. In this study, the HEK293T cell line, obtained from the German collection of microorgan-
isms and cell cultures (DSMZ), was used. Cells were routinely monitored for mycoplasma contamination using 
the Venor GeM Mycoplasma Detection Kit (Minerva Biolabs, Germany) and were negative. Unless otherwise 
stated, the cells were cultivated in DMEM containing 10% FCS (full medium) at 37 °C in a water-saturated atmos-
phere containing 5% CO2.
Generation of plasmids. Plasmids encoding different human GPCRs were obtained from the Missouri 
cDNA resource center (MO, USA). The other plasmids used were generated by standard PCR and restric-
tion techniques within the pcDNA backbone, unless otherwise stated. A plasmid encoding the red-emitting 
click-beetle luciferase (pCBR-control) was used as a template in different polymerase chain reactions (PCR) to 
generate the sequences encoding the two slightly overlapping N-terminal (CBRN, encoding amino acids 1–416) 
and C-terminal (CBRC, encoding amino acids 394–542) fragments of the luciferase. CBRN was then used to 
prepare plasmids encoding fusion proteins consisting of PLC-β3 fused either N- or C-terminally to CBRN. CBRC 
was used to generate plasmids of five different fusion proteins in which CBRC was fused to both termini of 
Gαq or integrated into the Gαq sequence after amino acids 66, 97 (Gαq(97)) and 123 (Gαq(123)), respectively. 
The linker sequences used to connect the luciferase fragments to either PLC-β3 or Gαq consisted of flexible Gly 
and Ser residues. The cDNA encoding the Gαq(123) fusion protein and the N-terminally-tagged PLC-β3 were 
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then subcloned into a pIRESpuro3 vector separated by a P2A autoproteolysis site37, yielding the pIRESpuro3 
CBRN-PLC-β3-2A-Gαq(123) vector. Cleavage of the P2A site was controlled by immunoblotting (Fig. S2). All 
plasmids were quality controlled by means of enzyme restriction analysis and sequencing.
Identification of the best pair of Gαq and PLC-β3 fusion proteins. HEK293T cells were seeded on a 
6-well plate (Sarstedt, Germany) at a density of 7 · 105 cell/well. The next day, the cells were transfected with plas-
mids encoding the different combinations of fusion proteins and the human histamine H1 receptor (hH1R). After 
48 h of incubation, the cells were detached by trypsinization, centrifuged and resuspended in DMEM devoid of 
phenol red, supplemented with FCS (5%). The concentration was adjusted to 1.11 · 106 cells/mL; 90 µL of this 
suspension were seeded into each well of a white 96-well plate (Greiner Bio One, Germany), and the cells were 
incubated overnight. To induce interaction of the two fusion proteins, histamine was added at a concentration of 
10 µM to the cells. In a control experiment, only DMEM without phenol red, the vehicle of histamine, was applied. 
After 25 min, 50 µL of medium were aspirated and replaced by 50 µL of Bright-Glo luciferase reagent. The cells 
were vigorously shaken for 2 min before luminescence was detected using a Genios Pro plate reader (Tecan) for 
1 s per well.
Generation of stable expression cell lines. HEK293T cells were transfected with the pIRESpuro3 
CBRN-PLC-β3-2A-Gαq(123) vector as described above. After two days of incubation, the cells were detached 
using trypsin and were seeded into a 75-cm2 cell culture flask. Then, the cells were allowed to attach and puro-
mycin was added at a concentration of 0.75 µg/mL. The cells were cultured upon changing the medium at regular 
Figure 1. Schematic illustration of the sensor principle and the fusion protein library used to determine 
the best combination of proteins. The activation of the Gαq pathway was probed by fusing complementary 
luciferase fragments to Gαq and PLC-β3 (A). A fusion protein library was generated by fusing CBRC to Gαq 
terminally and in three loop regions (numbers in parentheses denote amino acid positions) and by fusing 
CBRN either N-, or C-terminally to PLC-β3 (B). The different combinations of Gαq and PLC-β3 fusion proteins 
were expressed in HEK293T cells, co-expressing the hH1R. The relative increase in luminescence of cells 
stimulated with 10 µM histamine compared to unstimulated cells is shown for each combination (C). Data are 
presented as means ± SEM from three independent experiments, each performed in triplicate.
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intervals until stable growth was observed again. Subsequently, plasmids encoding cDNAs of GPCRs were trans-
fected in the same way, with the exception that selection was achieved in the presence of geneticin.
Quantification of agonistic potencies and antagonistic activities using the developed probe. 
Cells, expressing the developed Gαq/PLC-β3 sensor in combination with one of the GPCRs, were detached 
from a 75-cm2 flask by trypsinization and centrifuged (700 g for 5 min). The pellet was resuspended in assay 
medium consisting of L-15 with 5% FCS and the density of the suspension was adjusted to 1.25 · 106 cells/mL. 
Then, 80 µL of this suspension were seeded into each well of a 96-well plate, and the plate was incubated at 37 °C 
in a humidified atmosphere (without additional CO2) overnight. On the next day, 10 µL of 10 mM D-luciferin 
(Pierce) were added to the cells, and the plate was transferred into a pre-warmed microplate luminescence reader 
(either a Genios Pro (Tecan, Austria) or an EnSpire (Perkin-Elmer, Germany)). The cells were allowed to equili-
brate inside the reader for 10 min, before the basal luminescence was determined, by recording the luminescence 
for the entire plate ten times with an integration time of 1 s per well. In the meantime, serial dilutions of ago-
nists were prepared, the resulting solutions were also pre-warmed to 37 °C and subsequently added to the cells. 
Thereafter, luminescence was recorded for 30 plate repeats amounting to a time period of 50 min. Negative con-
trols (solvent) and positive controls (reference full agonist, histamine (hH1R), carbachol (hM1,5R), oxotremorine 
(hM3R)) eliciting a maximal response (100%) were included for subsequent normalization of the data. In case of 
the antagonist mode, antagonists were added 15 min prior to the initial thermal equilibration period to ensure an 
equilibrium between antagonists and receptors, before agonists were added. The pKb-values of antagonists were 
determined according to the Cheng-Prusoff equation38. FR900359 was pre-incubated for 20 min, before cells were 
stimulated with agonists. After acquisition of the data, the peak luminescence intensities obtained after stimula-
tion were used for quantitative analysis using Prism 5 (Graph Pad).
Fura-2 Ca2+ assay. HEK293T cells expressing either the hH1R alone, or co-expressing the Gαq/PLC-β3 
sensor, were incubated with Fura-2 AM analysed in cuvettes using a LS50 B luminescence spectrophotometer 
(Perkin-Elmer, Germany). Fura-2 calcium assays were essentially performed as described previously39.
Live cell luminescence microscopy. HEK293T cells, expressing hM3R and the Gαq/PLC-β3 sensor, were 
seeded on a 35-mm cell culture dish (Iwaki, Japan) in full medium at a density of 106 cells/dish and were incu-
bated overnight. The next day, 30 µL of 1 M HEPES buffer (pH 7.4) and 7.5 µL of 400 mM D-luciferin (Wako) 
were added. The cells were transferred to a IX-81 microscope (Olympus, Japan), equipped with a super-cooled 
EM-CCD camera (Hamamatsu photonics, Japan), with its stage heated to 37 °C, and bioluminescence microscopy 
was performed essentially as described25. Briefly, the images were acquired with an exposure time of 5 min per 
frame. After the first frame, oxotremorine was added to a final concentration of 100 nM. In case of the antagonist 
mode, atropine was added to a final concentration of 100 nM prior to the very first frame.
Results and Discussion
Development of the Gαq activation sensor. In a conventional approach to develop a SLC-based PPI 
probe, a set of fusion proteins, comprising the luciferase fragments and the two host proteins is engineered and 
expressed. Usually, both luciferase fragments are fused to both termini of the host proteins and all combinations 
of the resulting fusion proteins are analysed with respect to their ability to restore the luminescence signal. As our 
aim was to probe the Gαq/PLC-β3 interaction (Fig. 1A), and because Gαq is a rather small protein of which it is 
well known that both termini are of major importance for interactions with βγ-subunits, with a GPCR and the 
association with the cell membrane31–34, we pursued a slightly different strategy: we fused the smaller luciferase 
fragment (CBRC) to Gαq and incorporated CBRC into three different flexible loop regions, localized within the 
helical domain of Gαq40 (Fig. 1B). The complementing part of the luciferase (CBRN) was fused either to the N-, or 
the C-terminus of PLC-β3 (Fig. 1B). To identify the best combination of fusion proteins in terms of luminescence 
intensity and S/B ratio, we expressed all combinations of Gαq and PLC-β3 fusion proteins shown in Fig. 1B in 
HEK293T cells co-expressing the human histamine H1 receptor (hH1R). The resulting transfectants were stim-
ulated with 10 µM histamine for 25 min before the cells were lysed and the substrate was added. The detected 
luminescence was normalized i.e. divided by the luminescence intensity emitted from unstimulated cells. The low 
normalized luminescence shown in Fig. 1C suggests that the C-terminus of PLC-β3 is rather far away from the 
interaction site with Gαq. This is supported by the crystal structure of the Gαq/PLC-β3 complex40. The CBRN-
PLC-β3 fusion protein gave higher S/B ratios, especially when used in combination with the Gαq variant, in which 
CBRC was incorporated after amino acid 97 or 123. However, the overall luminescence intensity was higher for 
Gαq(123) (Fig. S1).
Although the construct, in which CBRC was N-terminally fused to Gαq, showed higher luminescence 
(Fig. S1), but only an S/B ratio comparable to that of Gαq(97) and Gαq(123), respectively, this fusion protein 
was not considered, because Yu et al. reported that an N-terminal fusion of green fluorescent protein to Gαs 
resulted in a lack of association with the cell membrane34. Therefore, we favoured Gαq(123) in combination with 
CBRN-PLC-β3.
We further optimized the sensor mainly with respect to handling. For this purpose, a vector plasmid, enabling 
convenient multi-cistronic expression of both fusion proteins in a fixed stoichiometry (1:1), using a self-cleaving 
P2A peptide sequence37, separating CBRN-PLC-β3 and Gαq(123), was constructed. Furthermore, we fabricated a 
HEK293T cell line, characterized by stable integration of the aforementioned plasmid into the genome as a versa-
tile platform for the analysis of different GPCRs upon co-transfection. Cleavage of the P2A sequence was proven 
by immunoblotting using an anti-Gαq antibody (Fig. S2). The western blots also revealed that the expression level 
of the modified Gαq was similar to that of endogenous Gαq in HEK293T cells (Fig. S2).
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Characterization of the new probe. To overcome the low S/B ratio, we added the substrate D-luciferin 
to live cells (in culture medium) rather than performing endpoint measurements after lysis of the cells. Thereby, 
we were able to follow the kinetics of the reaction (Fig. 2A). The sensor responded to an activation of the hH1R 
by increasing the concentration of histamine with a gradual increase in luminescence, which can be converted to 
a concentration-response-curve (CRC), yielding an EC50 value in very good agreement with data obtained from 
canonical assays3,16.
Additionally, we could show that the interaction of the two sensor proteins was fully reversible as demon-
strated in Fig. 2B. The addition of mepyramine, an hH1R-specific antagonist, after activation of the receptor 
with histamine (300 nM) led to a concentration-dependent decrease in luminescence, down to the background 
level. Similar experiments were performed with a sensor in which Gαq(123) was replaced by Gαq(97). The 
concentration-dependent response to histamine and the reversibility of the interaction of the two sensor proteins 
was still given, but the S/B ratio was approx. 3-fold lower (Fig. S3).
It turned out that the quality of D-luciferin, the pH of the surrounding medium and the temperature were 
critical for the validity of the results. D-luciferin from different suppliers was compared (data not shown) as a 
substrate of the developed probe, and only those products are listed in the method section, which afforded robust 
results. When experiments were performed at RT instead at 37 °C or in DMEM, in equilibrium with atmospheric 
CO2 (around 450 ppm), no or only very weak luminescence was detected (data not shown).
As shown in Fig. 2A, onset kinetics of the sensor was slower than expected for the activation of Gα subu-
nits18,41. We hypothesize that the observed slowdown is related to the folding of the full-length luciferase (matu-
ration) upon association of the two fragments22, thereby neither affecting the Gαq/PLC-β3 interaction itself nor 
downstream signalling. To prove this, we performed a Fura-2 Ca2+ assay, affording kinetic information on the 
transient increase in cytosolic Ca2+ with a high temporal resolution. Although the amplitudes of the Ca2+ tran-
sients were higher in the presence of the sensor (Fig. 2C) – presumably due to differences in cell density and/or by 
Figure 2. Characterization of the Gαq activation sensor. All experiments were performed with HEK293T 
cells, expressing the Gαq sensor and the hH1R, except for C were the sensor was not present. Increasing 
concentrations of histamine (addition indicated by arrow) lead to proportionally increasing luminescence 
emitted from the cells, which can be converted to a CRC (A). The opposite (a gradual decrease in luminescence) 
became obvious, when stimulated cells (300 nM histamine, first arrow) were subsequently treated with the 
selective hH1R agonist mepyramine (second arrow) (B). In case of the highest concentration, luminescence 
decreased to basal levels, indicating full reversibility of the sensor interaction. Since the observed activation 
kinetics in A was slower than expected for G protein activation, a kinetic Fura-2 assay for the quantification 
of [Ca2+]i was performed, to guarantee that the sensor does not negatively influence downstream signalling. 
In cells, in which the sensor was present, the kinetics was the same (C) when compared to cells devoid of the 
sensor (D). The concentration-dependent response to histamine (addition indicated by arrow) was similar 
(hH1R alone: pEC50: 7.1 ± 0.1; Gαq sensor present: pEC50: 6.8 ± 0.1), too. Furthermore, we were able to show 
that the modified Gαq as part of the sensor was still prone to inhibition by FR900359 (E). The sensor shows an 
exceptionally good Z’ of 0.7 (F). Data in A-D are representative of at least two independent experiments. Data in 
E are presented as mean along with their SEM from five independent experiments performed in triplicate. Data 
in F was obtained from an entire 96-well plate.
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an additional expression of exogenous Gαq and PLC-β3 proteins – the kinetics of intracellular Ca2+ mobilisation 
observed was nearly identical to that obtained from cells expressing the hH1R alone (Fig. 2D). Accordingly, the 
histamine concentration-dependent response was not influenced by the presence of the sensor.
The Gαq inhibitor FR900359 is a valuable tool for analysing signalling pathways involving Gαq3,42. Therefore, 
we examined the susceptibility of the modified Gαq to inhibition by FR900359 (Fig. 2E). We were able to inhibit 
sensor activation stepwise by applying FR900359 at increasing concentrations until the signal was totally abol-
ished at a concentration of 100 nM.
Furthermore, we were interested in the performance of the sensor, when applied in an assay for ligand char-
acterization. With S/B ratios around 5 (Fig. S3) and a Z’ value of 0.7 (Fig. 2F) the new probe should give excellent 
robust readouts in functional assays.
Characterization of reference ligands at five different GPCRs. Aiming at a sensor, broadly applicable 
to diverse Gαq-coupled GPCRs, especially to pharmacologically characterize ligands of the respective receptors, 
we analysed five different GPCRs of the histamine (hH1R), muscarinic acetylcholine (hM1,3,5R) and neurotensin 
(hNTS1R) family. Our focus lied on literature-described standard agonists in terms of potencies (pEC50) and effi-
cacies (Emax), as well as on antagonists concerning their antagonistic activity (pKb). The characterization always 
included a reference agonist that was able to maximally activate the receptor (defined as 100%). This was either 
the endogenous agonist or a pharmacologically comparable compound at the respective receptor. All other ana-
lysed ligands were normalized regarding their efficacy to the particular reference agonist (Table 1).
compound pEC50 %Emax N pKb N
hH1R
histamine 7.21 ± 0.07 100 8
UR-KUM530 8.22 ± 0.04 97.8 ± 3.6 7
histaprodifen 6.54 ± 0.07 95.6 ± 1.0 4
betahistine 5.95 ± 0.07 98.3 ± 2.1 4
mepyramine 8.48 ± 0.07 4
diphenhydramine 7.36 ± 0.07 5
cyproheptadine 10.12 ± 0.06 3
maprotiline 8.74 ± 0.10 4
hM1R
carbachol 6.12 ± 0.08 100 4
xanomeline 7.19 ± 0.17 80.6 ± 3.2 3
oxotremorine 7.32 ± 0.05 83.6 ± 1.8 3
iperoxo 9.42 ± 0.05 99.8 ± 2.3 4
N′-methyl scopolamine 9.35 ± 0.07 3
atropine 8.93 ± 0.05 3
propantheline 9.26 ± 0.05 3
pirenzepine 7.76 ± 0.05 3
hM3R
oxotremorine 7.09 ± 0.09 100 8
xanomeline 6.51 ± 0.11 87.2 ± 6.0 5
carbachol 6.65 ± 0.06 101.0 ± 4.9 5
iperoxo 9.24 ± 0.10 96.4 ± 1.3 4
N′-methyl scopolamine 9.34 ± 0.04 5
atropine 8.69 ± 0.08 5
propantheline 9.37 ± 0.05 5
pirenzepine 6.57 ± 0.03 5
hM5R
carbachol 6.78 ± 0.06 100 5
xanomeline 5.88 ± 0.14 73.3 ± 2.8 4
oxotremorine 7.19 ± 0.06 101.4 ± 4.3 4
iperoxo 9.80 ± 0.07 101.4 ± 1.1 4
N′-methyl scopolamine 9.52 ± 0.08 5
atropine 8.66 ± 0.05 5
propantheline 9.82 ± 0.08 5
pirenzepine 6.65 ± 0.09 5
hNTS1R
neurotensin (8–13) 8.79 ± 0.09 100 8
SR142948A 8.20 ± 0.06 4
Table 1. pEC50, Emax and pKb values of compounds analysed at the hH1R, the hM1,3,5Rs and the hNTS1R. Live 
HEK293T cells, expressing the developed sensor and the indicated receptor, were investigated regarding their 
response to standard agonists and antagonist. Data is given as mean ± SEM. N denotes the number of biological 
replicates, each determined in triplicate.
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At the hH1R, the endogenous agonist histamine, the slightly more potent phenylhistamine derivative 
UR-KUM530, histaprodifen and betahistine, a drug approved for the treatment of Ménière’s disease, were ana-
lysed (Fig. 3A). Except for histaprodifen, where luminescence decreased after having reached a plateau, com-
pounds gave robust CRCs. For histaprodifen and derivatives thereof, at higher concentrations toxic effects were 
reported3, which might compromise the luminescence signal. The obtained potencies – with no more than half 
an order of magnitude difference in EC50 – and efficacies were in good agreement with values obtained from the 
[32P]GTPase assay35,43 and results from assays addressing alternative signalling pathways, second messengers and 
holistic methods3. The only exception was histaprodifen, which was not always described as a full agonist as in 
our case3,16,35,44,45. Antagonistic activities of the reference ligands mepyramine, diphenhydramine, cyproheptadine 
and maprotiline also aligned well with values described in literature. The corresponding pKb-values differed no 
more than half a log unit, although especially cyproheptadine was described controversially with at least one and 
a half orders of magnitude difference in activity across different functional and competition binding assays3,43,46,47. 
For this compound, our data align best with those from competition binding and functional holistic assays3,46.
In literature, controversial data were reported for the analysed agonists at the muscarinic receptors, i.e. the 
ranges of potencies and efficacies for several compounds are very wide (Table S1). The potencies, we determined, 
fit well into the reported ranges, and, with a few exceptions, the efficacies too. For e.g. xanomeline at the hM3R, or 
oxotremorine at the hM5R, different Emax values were reported. Although the developed sensor delivers a readout 
proximal to the receptor, a potential receptor reserve might still influence the observed ligand efficacies48, which 
might be an explanation for the aforementioned discrepancies. This can, of course, also apply to most of the lit-
erature reported data. The determined activities (pKb values) of the hMxR antagonists were comparable to those 
obtained from other functional assays or pKi values from radioligand competition binding, with differences not 
greater than half an order of magnitude49–56.
In case of the peptidergic hNTS1R, the potency of NT(8–13) was comparable to that determined by BRET 
between G protein subunits57, or in a MAPK-dependent reporter gene assay58. The same holds true for the 
antagonist SR142948A, the pKb of which matches well with values obtained by IP3 quantification or radioligand 
binding59,60.
Live cell luminescence. To explore the potential of the developed probe in view of future applications, 
such as multiparametric measurements, e.g. in combination with impedance-based cell sensing, and imaging in 
laboratory animals, we decided to do live cell bioluminescence microscopy. For this purpose, cells, expressing the 
hM3R and the sensor, were investigated under an inverted microscope equipped with a super-cooled EM-CCD 
camera. Stimulation of the cells resulted in an increase in luminescence over time, whereas pre-incubation with 
the antagonist atropine abolished sensor activation completely, as shown in Fig. 4 and Videos S1 and S2. Although 
confocal resolution was not reached, luminescence was predominantly observed on the edges of the cells, indi-
cating sensor activation associated with the cellular membrane. These observations are in agreement with the fact 
that both sensor proteins are membrane-associated either due to palmytoylation as in case of Gαq or via hydro-
phobic regions as in the catalytic core of PLC-β340.
Figure 3. Characterization of standard ligands at the hH1R, the hM1,3,5R and the hNTS1R. Live HEK293T cells, 
stably expressing the developed sensor and the indicated receptor, were analysed regarding their response to 
standard agonists (A) and antagonists (B) for the respective receptors. The substrate D-luciferin was added 
directly to the cells, and the experiment was carried out at 37 °C. Agonist data was normalized to a reference 
full agonist for each receptor, maximal stimulation of which was defined as 100% (hH1R: histamine, hM1,5R: 
carbachol, hM3R: oxotremorine). pEC50, Emax and pKb values are listed in Table 1 and were in good accordance 
with data described in literature. Data are presented as means ± SEM of at least three independent experiments, 
each performed in triplicate. s.c.: solvent control.
www.nature.com/scientificreports/
8Scientific REPORTs |         (2018) 8:17179  | DOI:10.1038/s41598-018-35615-w
Conclusion
The SLC approach was applied to the interaction of Gαq and PLC-β3 involved in the signalling cascade of GPCRs. 
This led, to the best of our knowledge, to the first described SLC-based probe, in which one of the two luciferase 
fragments was incorporated into the protein sequence of one of the host proteins rather than attached to the 
termini. As a probe for the Gαq/PLC-β3 interaction that makes genetical receptor modifications unnecessary 
and with its excellent Z’ value of 0.7, the sensor is very suitable for ligand characterization, which was shown 
for five different GPCRs. Furthermore, the sensor proved to be useful for imaging, as shown for live cell biolu-
minescence microscopy. Beyond the here described applications the sensor might become a valuable tool for 
de-orphanization and subsequent determination of signalling pathways of orphan GPCRs, the analysis of Gαq 
activation in cells endogenously expressing Gαq protein-coupled receptors and imaging in laboratory animals.
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